Biosimilars Market Is Anticipated To Witness A Marked Growth During The Period Of 2016 To 2024

Biosimilars Market Is Anticipated To Witness A Marked Growth During The Period Of 2016 To 2024

“Biosimilars Market is expected to reach USD 41.7 billion by 2024. The industry is segmented on the basis of type of products and applications. With regard to the product type, the recombinant non-glycosylated segment is projected to flourish rapidly during the study period�

Biosimilars Market is expected to reach USD 41.7 billion by 2024, according to a new report by Grand View Research, Inc. The global biosimilars market is anticipated to witness a marked growth during the period of 2016 to 2024. The most significant factor leading to the growth of this industry is the fact that major biological drugs are nearing the patent cliff. Further, the lower cost of these drugs as compared to the patented biologics, the increasing encumbrance to cut down healthcare costs across the medical systems in the world, and the favourable clinical outcomes demonstrated through clinical trials for the biosimilar drugs is expected to boost the industry.

Access for Full Detail of Report and Complete TOC: http://www.grandviewresearch.com/industry-analysis/biosimilars-market

Follow Us:

For the purpose of this study, the major countries considered are the U.S., Canada, the UK, Germany, India, China, Brazil, and Russia. It was estimated that in 2015, Europe accounted for the largest market share of the global biosimilars market, followed by Asia Pacific.

The industry is segmented on the basis of type of products and applications. With regard to the product type, the recombinant non-glycosylated segment is projected to flourish rapidly during the study period. On the other hand, the recombinant glycosylated proteins segment is estimated to grow at a significant CAGR during the period 2015 to 2024 due to the increasing, wide spread incidence of cancer cases (24 million by 2035), which is identified as the crucial factor driving the growth of this sector.

Further key findings from the study suggest: 

North America is anticipated to be the fastest growing market during the forecast period. The biosimilars market has gained significant momentum in the U.S., presenting new opportunities for R&D and the manufacturing sector of biosimilars.



The European market is the most advanced one as it has been the first to formulate a regulatory pathway and adopt the use of biosimilars for more than 8 years now. Germany accounts for the maximum share in the biosimilars industry, followed by the rest of the European countries (UK, France, Spain, and Italy).



The Asia Pacific market is expected to witness a lucrative growth during the period 2015 to 2024. India and China are the key countries identified that are expected to lead the industry growth in the study period.

Follow Us:



The market for oncology is estimated to soar at a rapid pace in accordance with the increasing incidence of cancer cases in the world. Additionally, the demand for cost-effective cancer treatments is expected to further fuel the industry growth.



The biosimilars market comprises several local as well as global players. Some major players of this market include Amgen, Inc., Beacon Ltd., Tea Pharmaceutical Industries Ltd., Merck & Co., Milan, Inc., Dr. Reddy’s Laboratories, Inc., Sandoz, Inc., and Celltrion Healthcare Co., Ltd.

Read Our Blogs from Same Category By Grand View Research: http://www.grandviewresearch.com/blogs/healthcare Table of Content of Biosimilars Market Research Report: Chapter 1. Methodology and Scope 1.1. Research methodology 1.2. Research scope & assumption 1.3. List of data sources Chapter 2. Executive Summary 2.1. Biosimilars Market - Industry Summary and Key Buying Criteria, 2013 - 2024 Chapter 3. Market Snapshot Chapter 4. Market Variables, Trends & Scope 4.1. Market segmentation& scopes 4.2. Biosimilars: Market dynamics 4.2.1. Market driver analysis 4.2.1.1. Increasing emphasis on cutting down healthcare expenditures

Follow Us:

4.2.1.2. Cost effectiveness of biosimilar drugs 4.2.1.3. Positive outcome in the ongoing clinical trials 4.2.1.4. Increasing R&D investments 4.2.1.5. Patent expiration of biologics to boost the biosimilars market 4.2.2. Market restraint analysis 4.2.2.1. High manufacturing complexities and costs 4.2.2.2. Presence of non-original biologics and biobetters 4.3. Penetration & growth prospect mapping 4.4. Biosimilars – SWOT Analysis, By Factor (political & legal, economic and technological) 4.5. Industry Analysis – Porter’s Chapter 5. Biosimilars Market: Product Estimates & Trend Analysis 5.1. Biosimilars market: Product movement analysis 5.2. Recombinant Non-Glycosylated Proteins 5.2.1. Recombinant Non-Glycosylated Proteins Market Estimates and Forecast, 2013 to 2024 (USD Million) 5.2.1.1. Insulin 5.2.1.1.1. Market Estimates and Forecast, 2013 to 2024 (USD Million) 5.2.1.2. Human Growth Hormones 5.2.1.2.1. Market Estimates and Forecast, 2013 to 2024 (USD Million) 5.2.1.3. Granulocyte Colony-stimulating Factor (G-CSF) 5.2.1.3.1. Market Estimates and Forecast, 2013 to 2024 (USD Million) 5.2.1.4. Interferons

Follow Us:

5.2.1.4.1. Market Estimates and Forecast, 2013 to 2024 (USD Million) 5.3. Recombinant Glycosylated Proteins 5.3.1. Recombinant Glycosylated Proteins, Market Estimates and Forecast, 2013 to 2024 (USD Million) 5.3.1.1. Erythropoietin 5.3.1.1.1. Market Estimates and Forecast, 2013 to 2024 (USD Million) 5.3.1.2. Monoclonal Antibodies 5.3.1.2.1. Market Estimates and Forecast, 2013 to 2024 (USD Million) 5.3.1.3. Follitropin 5.3.1.3.1. Market Estimates and Forecast, 2013 to 2024 (USD Million) Chapter 6. Biosimilars Market: Application Estimates & Trend Analysis 6.1. Biosimilars market: Application movement analysis 6.2. Oncology 6.2.1. Market Estimates and Forecast, 2013 to 2024 (USD Million) 6.3. Blood Disorders 6.3.1. Market Estimates and Forecast, 2013 to 2024 (USD Million) 6.4. Growth Hormone Deficiency 6.4.1. Market Estimates and Forecast, 2013 to 2024 (USD Million) 6.5. Chronic And Autoimmune Disorders 6.5.1. Market Estimates and Forecast, 2013 to 2024 (USD Million) 6.6. Others 6.6.1. Market Estimates and Forecast, 2013 to 2024 (USD Million)

Follow Us:

Chapter 7. Biosimilars: Regional Estimates & Trend Analysis, by Product & Application 7.1. Biosimilars Market Share (%) Analysis, by Region, 2016&2024 7.2. North America 7.2.1. U.S. 7.2.1.1. U.S. biosimilars market, by product, 2013 – 2024 (USD Million) 7.2.1.2. U.S. biosimilars market, by application, 2013 – 2024 (USD Million) 7.2.2. Canada 7.2.2.1. Canada biosimilars market, by product, 2013 – 2024 (USD Million) 7.2.2.2. Canada biosimilars market, by application, 2013 – 2024 (USD Million) 7.3. Europe 7.3.1. Germany 7.3.1.1. Germany biosimilars market, by product, 2013 – 2024 (USD Million) 7.3.1.2. Germany biosimilars market, by application, 2013 – 2024 (USD Million) 7.3.2. UK 7.3.2.1. UK biosimilars market, by product, 2013 – 2024 (USD Million) 7.3.2.2. UK biosimilars market, by application, 2013 – 2024 (USD Million) 7.4. Asia Pacific

Follow Us:

7.4.1. China 7.4.1.1. China biosimilars market, by product, 2013 – 2024 (USD Million) 7.4.1.2. China biosimilars market, by application, 2013 – 2024 (USD Million) 7.4.2. India 7.4.2.1. India biosimilars market, by product, 2013 – 2024 (USD Million) 7.4.2.2. India biosimilars market, by application, 2013 – 2024 (USD Million) 7.5. Rest of the World 7.5.1. Brazil 7.5.1.1. Brazil biosimilars market, by product, 2013 – 2024 (USD Million) 7.5.1.2. Brazil biosimilars market, by application, 2013 – 2024 (USD Million) 7.5.2. Russia 7.5.2.1. Russia biosimilars market, by product, 2013 – 2024 (USD Million) 7.5.2.2. Russia biosimilars market, by application, 2013 – 2024 (USD Million) Chapter 8. Competitive Landscape 8.1. Strategy framework 8.2. Market participation categorization 8.3. Company Profiles 8.3.1. Amgen, Inc. 8.3.1.1. Company Overview

Follow Us:

8.3.1.2. Financial Performance 8.3.1.3. Product Benchmarking 8.3.1.4. Strategic Initiatives 8.3.2. Biocon Ltd. 8.3.2.1. Company Overview 8.3.2.2. Financial Performance 8.3.2.3. Product Benchmarking 8.3.2.4. Strategic Initiatives 8.3.3. Teva Pharmaceutical Industries Ltd. 8.3.3.1. Company Overview 8.3.3.2. Financial Performance 8.3.3.3. Product Benchmarking 8.3.3.4. Strategic Initiatives 8.3.4. Merck & Co. 8.3.4.1. Company Overview 8.3.4.2. Financial Performance 8.3.4.3. Product Benchmarking 8.3.4.4. Strategic Initiatives 8.3.5. Hospira, Inc. 8.3.5.1. Company Overview 8.3.5.2. Financial Performance 8.3.5.3. Product Benchmarking 8.3.5.4. Strategic Initiatives 8.3.6. Mylan Pharmaceuticals, Inc. 8.3.6.1. Company Overview 8.3.6.2. Financial Performance 8.3.6.3. Product Benchmarking

Follow Us:

8.3.6.4. Strategic Initiatives 8.3.7. Dr. Reddy’s Laboratories, Inc. 8.3.7.1. Company Overview 8.3.7.2. Financial Performance 8.3.7.3. Product Benchmarking 8.3.7.4. Strategic Initiatives 8.3.8. Sandoz, Inc. 8.3.8.1. Company Overview 8.3.8.2. Financial Performance 8.3.8.3. Product Benchmarking 8.3.8.4. Strategic Initiatives 8.3.9. Celltrion Healthcare Co. Ltd. 8.3.9.1. Company Overview 8.3.9.2. Financial Performance 8.3.9.3. Product Benchmarking 8.3.9.4. Strategic Initiatives 8.3.10. AbbVie, Inc. 8.3.10.1. Company Overview 8.3.10.2. Financial Performance 8.3.10.3. Product Benchmarking 8.3.10.4. Strategic Initiatives

Follow Us:

About Grand View Research, Inc.: Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc Phone: 1-415- 349-0058 Toll Free: 1-888- 202-9519 Email: sales@grandviewresearch.com Web – http://www.grandviewresearch.com/

Follow Us: